New Drug Extends Lives of Skin Cancer Patients

Monday, 14 Jul 2014 12:55 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

An experimental drug from Roche helped people with an advanced form of skin cancer live longer without their disease worsening when used in combination with another treatment, the Swiss drugmaker said on Monday.
 
Pharmaceutical companies are looking to combination therapy to yield better results and drug cocktails are expected to be crucial as oncologists seek to block cancer on multiple fronts.
 
Cobimetinib, which is being developed in collaboration with Exelixis Inc, is designed to be used with another Roche drug called Zelboraf for patients with tumors that have a mutation in a gene known as BRAF that allows melanoma cells to grow.
 
About half of all melanomas have the genetic aberration the drugs target.
 
Results of a Phase III study involving 495 patients previously untreated for advanced melanoma found those taking both drugs lived significantly longer without their disease worsening compared to those taking Zelboraf alone.
 
Roche plans to present the results at an upcoming medical meeting and said it would file the data for approval with health regulators worldwide
.
Melanoma globally afflicts more than 232,000 new people each year. While generally curable if caught early, it is one of the deadliest cancers in its advanced stages and there are few treatment options.
 
Cobimetinib works by blocking the activity of a protein called MEK, while Zelboraf - which is already approved in more than 80 countries - binds to the mutant protein BRAF.
 
Roche is also investigating cobimetinib in combination with other experimental medicines, including an immunotherapy for the treatment of non-small cell lung cancer and colorectal cancer.
 

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

New Fertility Treatment Cheaper, Effective

Wednesday, 22 Oct 2014 08:36 AM

A crucial part of conventional in vitro fertilization (IVF) -- the incubation of embryos in a laboratory dish -- can ins . . .

'Breakthrough' Peanut Allergy Treatment Hits Market

Wednesday, 22 Oct 2014 08:20 AM

French biotechfirm DBV Technologies - developer of what it says is a breakthrough treatment for peanut allergy sufferers . . .

Drugmakers to Join Forces to Make Millions of Ebola Vaccine Doses

Wednesday, 22 Oct 2014 08:11 AM

J J has simplified and fast-tracked its vaccine program in the light of the world's worst Ebola outbreak.
Leading d . . .

Most Commented

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved